Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis
Clin. transl. oncol. (Print)
; 18(1): 40-46, ene. 2016. tab
Artículo
en Inglés
| IBECS
| ID: ibc-148050
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Background. The role of bevacizumab in metastatic breast cancer is controversial. Identification of predictive biomarkers could help to select patients who really benefit from it. We evaluated the association of angiogenesis-related gene polymorphisms with the treatment outcome of bevacizumab in metastatic breast cancer patients. Patients and methods. eNOS-786T/C and -894G/T, IL-8-251T/A genomic polymorphisms were assessed in 31 metastatic breast cancer patients treated with bevacizumab plus chemotherapy in the first-line setting. Testing for association between each polymorphism and treatment outcome was performed. Results. Patients with IL-8 251 AA genotype showed a significantly lower progression-free survival in each combination comparison "TT" vs "AA" (13 vs 8 months; p = 0.008); TT vs TA vs AA (13 vs 11 vs 8 months; p = 0.02); TT vs TA +AA (13 vs 11 months; p = 0.01); TT + TA vs AA (12 vs 8 months; p = 0.01) and a lower overall survival when compared with TT +TA genotype (26 vs 51 months, p = 0.04). Patients carrying eNOS 894 TT genotype showed a statistically significant lower progression-free survival than patients with GG genotype (11.5 vs 26.5 months; p = 0.04) with no differences in the overall survival. No association with response rate was found with any of the polymorphisms analyzed. Conclusion. These findings suggest that IL-8 251T/A and eNOS-894 G/T polymorphisms might have a role in predicting treatment outcome of bevacizumab in metastatic breast cancer. Our results are hypothesis generating and need to be confirmed in larger clinical trials (AU)
RESUMEN
No disponible
Buscar en Google
Colección:
Bases de datos nacionales
/
España
Base de datos:
IBECS
Asunto principal:
Terapéutica
/
Neoplasias de la Mama
/
Preparaciones Farmacéuticas
/
Biomarcadores
/
Ensayos Clínicos como Asunto
/
Neovascularización Fisiológica
/
Análisis del Polimorfismo de Longitud de Fragmentos Amplificados
/
Supervivencia
Tipo de estudio:
Estudio de evaluación
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Clin. transl. oncol. (Print)
Año:
2016
Tipo del documento:
Artículo
Institución/País de afiliación:
Catholic University of the Sacred Heart/Italy
/
Catholic University/Italy